Helix BioPharma to Present Promising Cancer Treatment Findings at EMIM 2025

Helix BioPharma ( (TSE:HBP) ) just unveiled an announcement.

Helix BioPharma Corp. announced a poster presentation at the European Molecular Imaging Meeting in Bilbao, Spain, showcasing the effects of its Tumour Defence Breaker™, L-DOS47, on CEACAM6-expressing tumors. The study demonstrated that L-DOS47 effectively neutralizes the acidic tumor microenvironment, which is crucial for tumor progression, and showed promising results in head and neck cancer and colon adenocarcinoma models. These findings suggest that L-DOS47 could make hard-to-treat cancers more susceptible to treatment, potentially enhancing Helix’s position in the oncology field.

More about Helix BioPharma

Helix BioPharma Corp. is a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers. The company is known for its innovative approach in targeting the tumor microenvironment to improve cancer treatment outcomes.

YTD Price Performance: -1.12%

Average Trading Volume: 2,619

Technical Sentiment Consensus Rating: Buy

Current Market Cap: C$46.66M

Find detailed analytics on HBP stock on TipRanks’ Stock Analysis page.